QQQ3.70%

Trending

AMZN10.89%

Info

home Symbol ESLAnews

Exchange: NASDAQ·Updated 04:10 PM EDT

ESLAEstrella Biopharma Inc

$0.72

$0.059

(7.57%)

Today

Closed $0.7201

$0.0001

(0.01%)

After Hours

Mkt Cap$33.53M

Vol32,966.00

News

all

press releases

Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkins Lymphoma

Estrella Immunopharma, Inc. (NASDAQ: ESLA) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1...

Business Wire

More News

Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkins Lymphoma

Estrella Immunopharma, Inc. (NASDAQ: ESLA) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the...

Business Wire

Estrella Immunopharma to Participate in the D. Boral Capital Global Conference

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and...

Business Wire

Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLA) Declines By 57.6%

Estrella Immunopharma, Inc. (NASDAQ:ESLA - Get Free Report) was the recipient of a large decrease in short interest during the month of April. As of April 15th, there was short interest totaling 265,805 shares, a decrease of 57.6% from the March 31st total of 626,324 shares. Based on an average...

MarketBeat

Estrella Immunopharma (NASDAQ:ESLA) Trading Up 26.5% - Here's Why

Estrella Immunopharma (NASDAQ:ESLA) Shares Up 26.5% - Here's What Happened...

MarketBeat

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research

Business Wire

D. Boral Capital Reiterates Buy Rating for Estrella Immunopharma (NASDAQ:ESLA)

D. Boral Capital reissued a "buy" rating and issued a $8.00 price target on shares of Estrella Immunopharma in a research report on Monday...

MarketBeat

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT & CIBMTR

Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and...

Business Wire

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT & CIBMTR

Estrella Immunopharma, Inc. (Nasdaq: ESLA) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and...

Business Wire

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Estrella Immunopharma, Inc. (NASDAQ: ESLA) (the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune...

Business Wire

Advertisement|Remove ads.